ArticleBiomolecules2025
Bio-Inspired Mamba for Antibody-Antigen Interaction Prediction.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence-aware comparison of sequence-centric machine learning for antibody discovery and optimization.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antibody lead discovery, crucial for immunotherapy development, requires identifying candidates with potent binding affinities to target antigens. Recent advances in protein language models have opened promising avenues to tackle this challenge by predicting antibody-antigen interactions (AAIs). Despite their appeals, precisely detecting binding sites (i.e., paratopes and epitopes) within the complex landscape of long-sequence biomolecules remains challenging. Herein, we propose MambaAAI, a bio-inspired model built upon the Mamba architecture, designed to predict AAIs and identify binding sites through selective attention mechanisms. Technically, we employ ESM-2, a pre-trained protein language model to extract evolutionarily enriched representations from input antigen and antibody sequences, which are modeled as residue-level interaction matrixes. Subsequently, a dual-view Mamba encoder is devised to capture important binding patterns, by dynamically learning embeddings of interaction matrixes from both antibody and antigen perspectives. Finally, the learned embeddings are decoded using a multilayer perceptron to output interaction probabilities. MambaAAI provides a unique advantage, relative to prior techniques, in dynamically selecting bio-enhancing residue sites that contribute to AAI prediction. We evaluate MambaAAI on two large-scale antibody-antigen neutralization datasets, and in silico results demonstrate that our method marginally outperforms the state-of-the-art baselines in terms of prediction accuracy, while maintaining robust generalization to unseen antibodies and antigens. In further analysis of the selective attention mechanism, we found that MambaAAI successfully uncovers critical epitope and paratope regions in the SARS-CoV-2 antibody examples. It is believed that MambaAAI holds great potential to discover lead candidates targeting specific antigens at a lower burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.